» Articles » PMID: 27889762

Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs)

Overview
Date 2016 Nov 28
PMID 27889762
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Detection of CTCs is a poor prognostic factor for many cancer types; however, their very low frequency represents an obstacle for their detection. The objective of the current study was to compare the performance of commonly used methods for CTCs isolation.

Methods: The evaluated methods using spiking experiments of MCF7, SKBR3 and MDA MB-231 breast cancer cell lines were (i) ficoll density gradient separation (DGS), (ii) red blood cell lysis (Erythrolysis) isolation, (iii) positive immunomagnetic selection (EpCAM Dynal beads), (iv) two different negative immunomagnetic separation systems (Dynal vs Miltenyi CD45 beads) as well as (v) the Cell Search platform and (vi) the ISET system.

Results: The recovery rates of Erythrolysis and DGS were 39% and 24%, respectively. Magnetic isolations are ranked from the worse to the best recovery rate as follows:, Myltenyi-anti-CD45 microbeads (24%); Dynal-anti-EpCAM beads (75%); Dynabeads-anti-CD45 (97%). CTCs isolation from blood samples using the CellSearch and ISET systems revealed that the recovery rate for Cell Search and ISET was 52% and 95%, respectively.

Conclusions: Dynal-anti-CD45 beads have the best recovery rate compared to other magnetic methods. Furthermore the recovery rate of ISET was higher compared to Cell Search, especially for the more aggressive MDA-MB 231 cell line.

Citing Articles

Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.

Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).

PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.


Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.


Latest Research Progress of Liquid Biopsy in Tumor-A Narrative Review.

Jiang H Cancer Manag Res. 2024; 16:1031-1042.

PMID: 39165347 PMC: 11335005. DOI: 10.2147/CMAR.S479338.


Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.

Roumeliotou A, Strati A, Chamchougia F, Xagara A, Tserpeli V, Smilkou S Cells. 2024; 13(9.

PMID: 38727318 PMC: 11083423. DOI: 10.3390/cells13090782.


Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters.

Nguyen T, Huang P, Chu P, Hsieh C, Wu M Cancers (Basel). 2023; 15(22).

PMID: 38001632 PMC: 10670359. DOI: 10.3390/cancers15225372.